- Home
- CGEN vs ENTA Comparison
CGEN vs ENTA Comparison
Compare CGEN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- ENTA
- Stock Information
- Founded
- CGEN 1993
- ENTA 1995
- Country
- CGEN Israel
- ENTA United States
- Employees
- CGEN N/A
- ENTA N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CGEN Health Care
- ENTA Health Care
- Exchange
- CGEN Nasdaq
- ENTA Nasdaq
- Market Cap
- CGEN 142.8M
- ENTA 127.8M
- IPO Year
- CGEN 2000
- ENTA 2013
- Fundamental
- Price
- CGEN $1.60
- ENTA $5.89
- Analyst Decision
- CGEN Strong Buy
- ENTA Buy
- Analyst Count
- CGEN 2
- ENTA 4
- Target Price
- CGEN $4.00
- ENTA $19.50
- AVG Volume (30 Days)
- CGEN 445.1K
- ENTA 464.3K
- Earning Date
- CGEN 11-12-2024
- ENTA 02-05-2025
- Dividend Yield
- CGEN N/A
- ENTA N/A
- EPS Growth
- CGEN N/A
- ENTA N/A
- EPS
- CGEN 0.02
- ENTA N/A
- Revenue
- CGEN $59,852,000.00
- ENTA $67,635,000.00
- Revenue This Year
- CGEN $57.27
- ENTA $11.80
- Revenue Next Year
- CGEN N/A
- ENTA $3.99
- P/E Ratio
- CGEN $88.75
- ENTA N/A
- Revenue Growth
- CGEN 698.03
- ENTA N/A
- 52 Week Low
- CGEN $1.35
- ENTA $5.84
- 52 Week High
- CGEN $3.03
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- CGEN 51.01
- ENTA 24.81
- Support Level
- CGEN $1.55
- ENTA $5.84
- Resistance Level
- CGEN $1.68
- ENTA $6.56
- Average True Range (ATR)
- CGEN 0.08
- ENTA 0.73
- MACD
- CGEN 0.01
- ENTA -0.18
- Stochastic Oscillator
- CGEN 52.17
- ENTA 2.67
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.